Abstract: The present invention relates to the treatment and prevention of bone diseases in humans, including osteoporosis in postmenopausal women, Paget's Disease and hypercalcemia, by administration of a bisphosphonate in an inhalation form. The invention also relates to pharmaceutical inhalation compositions suitable for the treatment and prevention of bone diseases.

Abstract: A novel crystal form the pharmaceutical compound olanzapine, processes for its preparation and its pharmaceutical use are disclosed.

Abstract: This invention provides a process for preparing sodium ferric gluconate complex in sucrose using the following steps: a) combining a ferric salt solution with a weak alkali chosen from the group consisting of alkaline earth metal and ammonium salts, such as sodium carbonate, sodium bicarbonate, lithium carbonate, potassium carbonate, potassium bicarbonate, ammonium carbonate, ammonium bicarbonate and mixtures thereof, to form the ferric oxyhydroxide; b) combining ferric oxyhydroxide and sodium gluconate in solution to yield the sodium ferric gluconate complex; c) isolating the sodium ferric gluconate complex; and d) combining the sodium ferric gluconate with sucrose in solution to yield the desired sodium ferric gluconate complex in sucrose.

Abstract: A sample thief comprising: an outer hollow rod with an open end; a piston with a plunger end inserted within the outer hollow rod; and the outer hollow rod having an adjustable means. The thief operates by inserting the thief into a blend to be sampled just above the area of the blend to be sampled; adjusting the plunger so that a cavity greater than the desired sample size is created; compacting the sample into the thief; removing the thief from the blend; ejecting the excess sample to a predetermined point; and collecting the sample.

Abstract: A novel crystal form of ,&agr;-dimethyl-4-{1-hydroxy-4-{4-(hydroxydiphenylmethyl)-1-piperidinyl}butyl}benzeneacetic acid hydrochloride, processes for its preparation and its pharmaceutical use are disclosed.

Abstract: This disclosure relates to the use of &agr;,&agr;-dibromo-&agr;-chloroacetophenone compounds as intermediates for the preparation of aromatic carbonyl compounds, especially aromatic amides. The compound 2,5-bis(2,2,2-trifluoroethoxy)-&agr;,&agr;-dibromo-&agr;-chloroacetophenone is especially useful as an intermediate for the preparation of flecainide, a known pharmaceutical.

Abstract: This disclosure relates to the use of &agr;,&agr;-dibromo-&agr;-chloroacetophenone compounds as intermediates for the preparation of aromatic carbonyl compounds, especially aromatic amides. The compound 2,5-bis(2,2,2-trifluoroethoxy)-&agr;,&agr;-dibromo-&agr;-chloroacetophenone is especially useful as an intermediate for the preparation of flecainide, a known pharmaceutical.

Abstract: Midodrine hydrochloride, ±1-(2′,5′-dimethoxyphenyl)-2-glycineamido-ethanol-(1)-HCl, is prepared from a novel intermediate, 1-(2′,5′-dimethoxyphenyl)-2-azidoethanone.

Abstract: Disclosed herein is a solid oral dosage form comprising bromocriptine and one or more pharmaceutically acceptable excipients. The oral dosage form has a dissolution rate in excess of 90% in 5 minutes in 500 ml of 0.1N HCl aqueous medium at 37 C and is useful for adjusting the plasma prolactin profile of a patient.